SEMA3A and neoplasm: A recent study conducted by Mike B. Barnkob et al. shows the role of Sema3A in anti-tumor immunity, they observed that NRP1 and PlexinA1 and Plexin A4 are upregulated in tumor specific CD8+ T cells and NRP1 deficiency enhances anti-tumor activity of CD8+ T cells against Sema3A rich tumors [72].